Condition: Renal Cell Carcinoma · Sponsor: Xynomic Pharmaceuticals, Inc.
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
This description comes directly from the study's public registry record.
Sophia Paspal, Ph.D. · 6104055974 · sophia.paspal@xynomicpharma.com
Rahul Aggarwal, M.D. · rahul.aggarwal@ucsf.edu
Always discuss trial participation with your own doctor first.
| University Of UA Cancer Center(UACC)/DH-SJHMC | Phoenix, Arizona, United States | Withdrawn |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Withdrawn |
| UCSF Helen Diller Family Comphrensive Cancer Center - Hemato | San Francisco, California, United States | Withdrawn |
| Norton Cancer Institute, Norton Healthcare Pavilion | Louisville, Kentucky, United States | Completed |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | Completed |
| GU Research Network/Urology Cancer Center | Omaha, Nebraska, United States | Withdrawn |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Completed |
| Northwell Health/Monter Cancer Center | Lake Success, New York, United States | Withdrawn |
| Mainstreet Physicans Care | Rochester, New York, United States | Completed |
| Precision Cancer Research/Dayton Physicians Network - Treatment | Kettering, Ohio, United States | Withdrawn |
| Oregon Health and Science University | Portland, Oregon, United States | Completed |
| St. Luke's Hospital | Easton, Pennsylvania, United States | Completed |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03592472